Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2019 · 10-Q
Revenue—
Net Income-$2.79M-$2.79MN/M vs Q2 2018 EPS Diluted-$0.05-$0.05N/M vs Q2 2018 Operating Income-$2,279,000N/M Operating Cash Flowderived-$1,087,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,087,000N/M ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end